Predictive value of B-type natriuretic peptide levels in patients with paroxysmal and persistent atrial fibrillation undergoing pulmonary vein isolation.
BACKGROUND
Atrial fibrillation (AF) is the most common cardiac arrhythmia reducing the health-related quality of life. Radiofrequency catheter ablation (CA) became the therapy of choice in patients with drug-resistant AF with success rates between 30% and 86%. However, CA remains a challenging intervention with major complications in about 5% of cases. Therefore, stratification into high and low success patient groups would be helpful. The aim of this study was to investigate the predictive value of B-type natriuretic peptide (BNP) on the outcome of pulmonary vein isolation (PVI) in patients with paroxysmal (PAF) and persistent (Pers-AF) atrial fibrillation.


METHODS
In 73 patients (median age 53 years, 77% men) undergoing PVI for drug-refractory PAF (n = 45) or Pers-AF (n = 28), the serum BNP concentration was measured before and 3 months after the ablation procedure to assess any association of pre- and post-interventional BNP concentrations with therapeutic outcome. The patients had suffered from AF for a median of 40 months. No patient had structural heart disease or an impaired left-ventricular ejection fraction.


RESULTS
A total of 54 patients (74%) had stable sinus rhythm 3 months after PVI. The median baseline BNP levels in both PAF and Pers-AF patients were significantly lower in patients with a 3-month successful PVI than those in which it was unsuccessful, 57.5 pg/ml (20.4-87.9) versus 159.0 pg/ml (124.1-177.5; p = 0.001) in PAF patients and 90.3 pg/ml (41.0-155.0) versus 176 pg/ml (89.6-297.4; p = 0.026) in patients with Pers-AF, respectively. A multiple logistic regression analysis identified pre-interventional BNP levels as the only independent predictor for 3-month PVI outcomes (p = 0.010). Nevertheless, in this study, the predictive value of BNP for PVI outcomes was not high enough to permit individual outcome prediction. After successful PVI, BNP levels were significantly lower in patients with PAF and Pers-AF (median changes -16.9 and -23.8 pg/ml; p = 0.010 and p = 0.022, respectively), but not in patients with AF in follow-up (median change 9.0 pg/ml and -29.6 pg/ml; p = 1.000 and p = 0.109, respectively).


CONCLUSIONS
Pre-ablation BNP level seems to be an independent marker for successful PVI procedures in patients with paroxysmal and persistent AF; however, the observed level of association is moderate.
Department of Cardiology and Electrophysiology, University of Witten/Herdecke, Medical Center Porz am Rhein, Cologne, Germany.
Stephan
S
Degener
Sarah V
SV
Pattberg
Henrike
H
Feuersenger
Paul M
PM
Bansmann
Dong-In
DI
Shin
Frank
F
Krummenauer
Marc
M
Horlitz
D001281:Atrial Fibrillation / Q000097:blood* / Q000601:surgery*; D015415:Biomarkers / Q000097:blood; D017115:Catheter Ablation / Q000379:methods*; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D011237:Predictive Value of Tests; D011667:Pulmonary Veins / Q000601:surgery; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
D015415:Biomarkers; D020097:Natriuretic Peptide, Brain
Scand J Clin Lab Invest. 2009;69(8):843-50
19929271
Europace. 2007 Sep;9(9):770-4
17670784
Am J Cardiol. 2003 Nov 1;92(9):1124-7
14583372
Indian Pacing Electrophysiol J. 2009 Sep 01;9(5):241-6
19763191
Int J Cardiol. 2007 May 31;118(2):145-50
16959341
Curr Cardiol Rev. 2009 May;5(2):112-8
20436851
J Cardiovasc Electrophysiol. 2007 Jan;18(1):69-74
17081214
Eur Heart J. 2006 Jul;27(14):1648-50
16785247
Circulation. 1997 Feb 4;95(3):572-6
9024141
Circulation. 2004 Feb 10;109(5):594-600
14769680
Am J Cardiol. 2006 Jun 15;97(12):1741-4
16765125
Cardiol J. 2008;15(6):525-9
19039756
Am Heart J. 1996 Apr;131(4):790-5
8721656
Mayo Clin Proc. 2005 Aug;80(8):1029-36
16092582
J Cardiovasc Electrophysiol. 2008 Jul;19(7):661-7
18284502
J Interv Card Electrophysiol. 2004 Jun;10(3):221-6
15133358
J Am Coll Cardiol. 2002 Sep 4;40(5):976-82
12225726
Am J Cardiol. 2004 Oct 1;94(7):945-7
15464685
Am J Cardiol. 2002 Aug 1;90(3):254-8
12127613
Circ Arrhythm Electrophysiol. 2009 Aug;2(4):349-61
19808490
Europace. 2007 Jun;9(6):335-79
17599941
Am J Med. 2006 May;119(5):448.e1-19
16651058
Circulation. 1998 Sep 8;98(10):946-52
9737513
J Cardiovasc Electrophysiol. 2009 Sep;20(9):1005-10
19493152
Cardiol Rev. 2008 Jul-Aug;16(4):181-8
18562808
Circulation. 2002 Feb 5;105(5):595-601
11827925
J Am Coll Cardiol. 2009 Aug 25;54(9):788-95
19695455
Circ Arrhythm Electrophysiol. 2010 Feb;3(1):32-8
19995881
Nature. 2002 Jan 10;415(6868):219-26
11805846
Am J Cardiol. 2005 Jun 1;95(11):1380-2
15904651
Circulation. 2002 Mar 5;105(9):1077-81
11877358
Circulation. 1999 Nov 2;100(18):1879-86
10545432
Circ Arrhythm Electrophysiol. 2010 Jun;3(3):237-42
20335557
Pacing Clin Electrophysiol. 2009 Jun;32(6):745-52
19545336
Circ J. 2007 Mar;71(3):313-20
17322627
J Interv Card Electrophysiol. 2006 Apr;15(3):157-63
16955362
Heart. 2006 Nov;92(11):1623-7
16740921
Europace. 2008 Sep;10(9):1073-8
18628258
N Engl J Med. 1998 Sep 3;339(10):659-66
9725923